Time course of changes in the clinical manifestations of gout in men: Data of a 7-year retrospective follow-up


Cite item

Full Text

Abstract

Aim. To estimate the time course of changes in the clinical manifestations of gout and their risk factors during a long-term follow-up. Subjects and methods. A total of 160 male patients with gout were examined and followed up for a mean of 6.9±2.0 years. Their clinical assessment included determination of the type of arthritis over time, the frequency of arthritis attacks during one year prior to the examination, the presence and number of subcutaneous tophi, inflamed joints, comorbid or co-occurring diseases (CD), allopurinol adherence, dietary compliance, frequency of taking non-steroidal anti-inflammatory drugs (NSAIDs), diuretics, and alcohol. The serum levels of uric acid (UA), glucose, total cholesterol, and glomerular filtration rate were estimated. Results. The number of patients taking allopurinol increased from 19% to 64% (р<0.0001), its average daily dose was 167.6±94.6 mg. The serum level of UA decreased; 16% of the patients achieved its target level. The number of patients with chronic arthritis was not significantly changed. Their serum level of UA was unchanged; the detection rate of subcutaneous tophi and CD rose. During one year, arthritis attacks were absent in 13% of the patients; 90% of them took allopurinol. In these patients, serum UA levels and body mass index significantly declined and the rate of CD was unchanged. None of 18 patients who had their diet and no allopurinol achieved the target level of UA. Conclusion. Among the gouty patients, 36% refrain from the use of allopurinol, only 23% out of them require that its dose be adjusted to achieve the target level of UA. Dietary compliance is insufficient to reach the target level of UA. Chronic arthritis is associated with the increased incidence of CD.

References

  1. Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis. 2014 Jan 15. doi: 10.1136/annrheumdis-2013—204463.
  2. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007—2008. Arthritis Rheum. 2011;63(10):3136-3141. doi: 10.1002/art.30520.
  3. Барскова В.Г. Хроническая подагра: причины развития, клинические проявления, лечение. Терапевтический архив. 2010;1(87):64-68.
  4. Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum. 2002;47:356-360.
  5. Sarawate CA, Patel PA, Schumacher HR, Yang W, Brewer KK, Bakst AW. Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol. 2006;12(2):61-65.
  6. Dalbeth N, Ames R, Gamble GD, Horne A, Wong S, Kuhn-Sherlock B, MacGibbon A, McQueen FM, Reid IR, Palmano K. Effects of skim milk powder enriched with glycomacropeptide and G600 milk fat extract on frequency of gout flares: a proof-of-concept randomized controlled trial. AnRheum Dis. 2012;71(6):929-934. doi: 10.1136/annrheumdis-2011-200156.
  7. Reinders MK, Haagsma C, Jansen TL, van Roon EN, Delsing J, van de Laar MA, Brouwers JR. A randomized controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300—600 мг/day versus benzbromarone 100—200 mg/day in patients with gout. Ann Rheum Dis. 2009;68:892-897. doi: 10.1136/ard.2008.091462.
  8. Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, Lademacher C, Joseph-Ridge N. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008;59(11):1540-1548. doi: 10.1002/art.24209.
  9. Vazguez-Mellado J, Garsia CG, Vazguez SG, Medrano G, Ornelas M, Alcocer L, Marquez A, Burgos-Vargas R. Metaolic syndrome and ischemic heart disease in gout. J Clin Rheumatol. 2004;10(3):105-109.
  10. Насонова В.А., Елисеев М.С., Барскова В.Г. Влияние возраста на частоту и выраженность признаков метаболического синдрома у больных подагрой. Современная ревматология. 2007;1:31-36.
  11. Zhang Y, Neogi T, Chen C, Chaisson C, Hunter DJ, Choi H. Low-dose aspirin use and recurrent gout attacks. Ann Rheum Dis 2014;73(2):385-390. doi: 10.1136/annrheumdis-2012-202589.
  12. Hueskes BA, Willems FF, Leen AC, Ninaber PA, Westra R, Mantel-Teeuwisse AK, Janssens HJ, van de Lisdonk EH, Roovers EA, Janssen M. A case-control study of determinants for the occurrence of gouty arthritis in heart failure patients. Eur J Heart Fail. 2012;14(8):916-921. doi: 10.1093/eurjhf/hfs086.
  13. Wertheimer A, Morlock R, Becker MA. A revised estimate of the burden of illness of gout. Curr Ther Res Clin Exp. 2013;75:1-4. doi: 10.1016/j.curtheres.2013.04.003.
  14. Perez-Ruiz F, Martinez-Indart L, Carmona L, Herrero-Beites AM, Pijoan JI, Krishnan E. Presence of tophi and high level hyperuricemia are associated with increased risk of mortality in patients with gout. Ann Rheum Dis. 2012;71(Suppl 3):87. doi: 10.1136/annrheumdis-2012-202421.
  15. Dessein PH, Shipton EA, Stanwix AE, Joffe BI, Ramokgadi J. Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study. Ann Rheum Dis. 2000;59(7):539-543. doi: 10.1136/ard.59.7.539.
  16. Langeveld M, de Vries JH. The mediocre results of dieting. Ned Tijdschr Geneeskd. 2013;157(29):A6017.
  17. Singh JA, Reddy SG, Kundukulam J. Risk factors for gout and prevention: a systematic review of the literature. Curr Opin Rheumatol. 2011;23:192-202. doi: 10.1097/BOR.0b013e3283438e13.
  18. Dalbeth N, House ME, Horne A, Petrie KJ, McQueen FM, Taylor WJ. Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout. BMC Musculoskelet Disord. 2012;13:174. doi: 10.1186/1471-2474-13-174.
  19. Singh JA, Nodges JS, Asch SM. Opportunities for improving medication use and monitoring in gout. Ann Rheum Dis. 2009;68:1265-1270. doi: 10.1136/ard.2008.092619.
  20. Grimaldi-Bensouda L, Alpérovitch A, Aubrun E, Danchin N, Rossignol M, Abenhaim L, Richette P; the PGRx MI Group. Impact of allopurinol on risk of myocardial infarction. Ann Rheum Dis. 2014 Jan 6. doi: 10.1136/annrheumdis-2012-202972.
  21. Kanbay M, Ozkara A, Selcoki Y, Isik B, Turgut F, Bavbek N, Uz E, Akcay A, Yigitoglu R, Covic A. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions. Int Urol Nephrol. 2007;39(4):1227-1233.
  22. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA. 2008;300(8):924-932. doi: 10.1001/jama.300.8.924.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies